H1-Antihistamines Reduce the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus, Hepatitis C Virus, or Dual Hepatitis B Virus-Hepatitis C Virus Infection

H1-Antihistamines Reduce the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus, Hepatitis C Virus, or Dual Hepatitis B Virus-Hepatitis C Virus Infection

PURPOSE: H1-antihistamines (AHs) may exert protective effects against cancer. This study investigated the association of AH use with the risk of hepatocellular carcinoma (HCC) in patients with hepatitis B virus (HBV), hepatitis C virus (HCV), or dual HBV-HCV virus infection. MATERIALS AND METHODS: P...

Full description

Bibliographic Details
Main Authors: Chang, C.-C (Author), Chang, Y.-S (Author), Chen, J.-H (Author), Chen, L.-F (Author), Chen, W.-S (Author), Hsu, H.-C (Author), Hu, L.-F (Author), Kuo, P.-I (Author), Liang, Y.-C (Author), Lin, S.-H (Author), Lin, T.-M (Author), Lin, Y.-C (Author), Shen, Y.-C (Author)
Format: Article
Language:English
Published: NLM (Medline) 2022
Subjects:
antihistaminic agent
Carcinoma, Hepatocellular
complication
Hepacivirus
hepatitis B
Hepatitis B
Hepatitis B virus
hepatitis C
Hepatitis C
Histamine Antagonists
human
Humans
liver cell carcinoma
Liver Neoplasms
liver tumor
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items